{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:24:05Z","timestamp":1787502245346,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,23]]},"DOI":"10.7759\/cureus.115032","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:39:45Z","timestamp":1787499585000},"source":"Crossref","is-referenced-by-count":0,"title":["Health-Related Quality of Life and Cost-Effectiveness of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Monotherapy in Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Subodh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv K","family":"Mudgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seshadri Reddy","family":"Varikasuvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Mahato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradosh Kumar","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himel","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha A","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015, 5:2892-911.","journal-title":"Am J Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria JC","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al.. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018, 378:113-25. 10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam SS","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al.. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020, 382:41-50. 10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park K","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, et al.. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016, 17:577-89. 10.1016\/S1470-2045(16)30033-X","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.006","article-title":"Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","volume":"125","author":"Leighl NB","year":"2020","unstructured":"Leighl NB, Karaseva N, Nakagawa K, et al.. Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer. 2020, 125:49-57. 10.1016\/j.ejca.2019.11.006","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0888","article-title":"The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050","volume":"17","author":"Paty J","year":"2021","unstructured":"Paty J, Sandin R, Reisman A, et al.. The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. Future Oncol. 2021, 17:783-94. 10.2217\/fon-2020-0888","journal-title":"Future Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101122","article-title":"Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer","volume":"48","author":"Shi Y","year":"2024","unstructured":"Shi Y, Chen G, Wang X, et al.. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. Lancet Reg Health West Pac. 2024, 48:101122. 10.1016\/j.lanwpc.2024.101122","journal-title":"Lancet Reg Health West Pac"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03438-3","article-title":"What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis","volume":"24","author":"Zhang W","year":"2024","unstructured":"Zhang W, Zhang X, Zhao W, et al.. What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis. BMC Pulm Med. 2024, 24:620. 10.1186\/s12890-024-03438-3","journal-title":"BMC Pulm Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13168-8","article-title":"EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis","volume":"24","author":"Liu A","year":"2024","unstructured":"Liu A, Wang X, Wang L, et al.. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis. BMC Cancer. 2024, 24:1390. 10.1186\/s12885-024-13168-8","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","volume":"367","author":"Zhao Y","year":"2019","unstructured":"Zhao Y, Liu J, Cai X, et al.. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2019, 367:l5460. 10.1136\/bmj.l5460","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819674","article-title":"Cost-effectiveness of 12 first-line treatments for patients with advanced EGFR mutated NSCLC in the United Kingdom and China","volume":"12","author":"Guan H","year":"2022","unstructured":"Guan H, Wang C, Chen C, Han S, Zhao Z. Cost-effectiveness of 12 first-line treatments for patients with advanced EGFR mutated NSCLC in the United Kingdom and China. Front Oncol. 2022, 12:819674. 10.3389\/fonc.2022.819674","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref15","article-title":"","author":"Drummond MF","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Fourth Edition. Oxford University Press, Oxford, UK; 2015. https:\/\/global.oup.com\/academic\/product\/methods-for-the-economic-evaluation-of-health-care-programmes-9780199665884."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.07.013","article-title":"Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non-small cell lung cancers","volume":"12","author":"Chouaid C","year":"2017","unstructured":"Chouaid C, Luciani L, LeLay K, et al.. Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non-small cell lung cancers. J Thorac Oncol. 2017, 12:1496-502. 10.1016\/j.jtho.2017.07.013","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S293983","article-title":"Cost-effectiveness analysis of dacomitinib versus gefitinib in the first-line treatment of EGFR-positive advanced or metastatic non-small cell lung cancer","volume":"13","author":"Zhang L","year":"2021","unstructured":"Zhang L, Li N, Liu M, Zheng B, Wu Z, Cai H. Cost-effectiveness analysis of dacomitinib versus gefitinib in the first-line treatment of EGFR-positive advanced or metastatic non-small cell lung cancer. Cancer Manag Res. 2021, 13:4263-70. 10.2147\/CMAR.S293983","journal-title":"Cancer Manag Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1395","article-title":"Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer","volume":"4","author":"Aguiar PN Jr","year":"2018","unstructured":"Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, de Lima Lopes G Jr. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. JAMA Oncol. 2018, 4:1080-4. 10.1001\/jamaoncol.2018.1395","journal-title":"JAMA Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2395803","article-title":"Cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer","volume":"20","author":"Zhang H","year":"2024","unstructured":"Zhang H, Zheng X, Zhang Y, Wang J. Cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer. Future Oncol. 2024, 20:2661-70. 10.1080\/14796694.2024.2395803","journal-title":"Future Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1527614","article-title":"Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations","volume":"16","author":"Zhang H","year":"2025","unstructured":"Zhang H, Li Y, Liu Y, Li H, Wang H. Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations. Front Pharmacol. 2025, 16:1527614. 10.3389\/fphar.2025.1527614","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522822-health-related-quality-of-life-and-cost-effectiveness-of-first-line-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitor-monotherapy-in-advanced-egfr-mutated-non-small-cell-lung-cancer-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:39:46Z","timestamp":1787499586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522822-health-related-quality-of-life-and-cost-effectiveness-of-first-line-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitor-monotherapy-in-advanced-egfr-mutated-non-small-cell-lung-cancer-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.115032","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}